Atai Life Sciences Stock Current Valuation
| ATAI Stock | USD 1.39 0.09 6.08% |
Valuation analysis of ATAI Life Sciences helps investors to measure ATAI Life's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. The ATAI Life's current Enterprise Value is estimated to increase to about 207.9 M, while Enterprise Value Over EBITDA is projected to decrease to (5.73). Fundamental drivers impacting ATAI Life's valuation include:
Price Book 1.7043 | Enterprise Value 186.2 M | Enterprise Value Ebitda 0.2655 | Price Sales 750.2929 | Enterprise Value Revenue 562.6421 |
Undervalued
Today
Please note that ATAI Life's price fluctuation is risky at this time. Calculation of the real value of ATAI Life Sciences is based on 3 months time horizon. Increasing ATAI Life's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since ATAI Life is currently traded on the exchange, buyers and sellers on that exchange determine the market value of ATAI Stock. However, ATAI Life's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.39 | Real 4.08 | Target 12.32 | Hype 1.4 | Naive 1.22 |
The intrinsic value of ATAI Life's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence ATAI Life's stock price.
Estimating the potential upside or downside of ATAI Life Sciences helps investors to forecast how ATAI stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of ATAI Life more accurately as focusing exclusively on ATAI Life's fundamentals will not take into account other important factors: ATAI Life Sciences Company Current Valuation Analysis
ATAI Life's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current ATAI Life Current Valuation | 186.23 M |
Most of ATAI Life's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ATAI Life Sciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
ATAI Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for ATAI Life is extremely important. It helps to project a fair market value of ATAI Stock properly, considering its historical fundamentals such as Current Valuation. Since ATAI Life's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of ATAI Life's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of ATAI Life's interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, ATAI Life Sciences has a Current Valuation of 186.23 M. This is 98.7% lower than that of the Biotechnology sector and 95.99% lower than that of the Health Care industry. The current valuation for all United States stocks is 98.88% higher than that of the company.
ATAI Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ATAI Life's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ATAI Life could also be used in its relative valuation, which is a method of valuing ATAI Life by comparing valuation metrics of similar companies.ATAI Life is currently under evaluation in current valuation category among its peers.
ATAI Fundamentals
| Return On Equity | -0.63 | ||||
| Return On Asset | -0.25 | ||||
| Operating Margin | (565.05) % | ||||
| Current Valuation | 186.23 M | ||||
| Shares Outstanding | 167.8 M | ||||
| Shares Owned By Insiders | 9.98 % | ||||
| Shares Owned By Institutions | 26.76 % | ||||
| Number Of Shares Shorted | 10.2 M | ||||
| Price To Earning | 0.30 X | ||||
| Price To Book | 1.70 X | ||||
| Price To Sales | 750.29 X | ||||
| Revenue | 314 K | ||||
| Gross Profit | 233 K | ||||
| EBITDA | (36.31 M) | ||||
| Net Income | (40.22 M) | ||||
| Cash And Equivalents | 304.06 M | ||||
| Cash Per Share | 1.83 X | ||||
| Total Debt | 19.14 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 12.25 X | ||||
| Book Value Per Share | 0.91 X | ||||
| Cash Flow From Operations | (84.12 M) | ||||
| Short Ratio | 4.71 X | ||||
| Earnings Per Share | (0.80) X | ||||
| Target Price | 8.0 | ||||
| Number Of Employees | 83 | ||||
| Beta | 0.78 | ||||
| Market Capitalization | 248.35 M | ||||
| Total Asset | 293.48 M | ||||
| Retained Earnings | (550.94 M) | ||||
| Working Capital | 165.47 M | ||||
| Current Asset | 320.15 M | ||||
| Current Liabilities | 74.35 M | ||||
| Net Asset | 293.48 M |
About ATAI Life Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ATAI Life Sciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ATAI Life using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ATAI Life Sciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether ATAI Life Sciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ATAI Life's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Atai Life Sciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Atai Life Sciences Stock:Check out ATAI Life Piotroski F Score and ATAI Life Altman Z Score analysis. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ATAI Life. If investors know ATAI will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ATAI Life listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.97) | Earnings Share (0.80) | Revenue Per Share 0.002 | Quarterly Revenue Growth (0.54) | Return On Assets (0.25) |
The market value of ATAI Life Sciences is measured differently than its book value, which is the value of ATAI that is recorded on the company's balance sheet. Investors also form their own opinion of ATAI Life's value that differs from its market value or its book value, called intrinsic value, which is ATAI Life's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ATAI Life's market value can be influenced by many factors that don't directly affect ATAI Life's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ATAI Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if ATAI Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ATAI Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.